Table II.

Lipid nanoparticle-based formulations of selected RNA therapeutics currently under clinical investigation.

Disease condition	Formulation and mRNA dose (when known)	Company/entity	Clinical trial phase	Clinical trial registry
SARS-CoV-2	BNT162b2 (30 $\mathrm{\mu }$g)	Pfizer/BioNTech SE	EUA/CMA	NCT04368728
SARS-CoV-2	mRNA-1273 (100 $\mathrm{\mu }$g)	ModernaTX, Inc., BARDA, NIAID	EUA/CMA	NCT04470427
SARS-CoV-2	CVnCoV (12 $\mathrm{\mu }$g)	CureVac AG	III	NCT04652102
SARS-CoV-2	ARCT-021 (7.5 $\mathrm{\mu }$g or 2$\times$ 5 $\mathrm{\mu }$g)	Arcturus Therapeutics, Inc.	II	NCT04728347
SARS-CoV-2	DS-5670a (10, 30, 60 or 100 $\mathrm{\mu }$g)	Daiichi Sankyo Co., Ltd.	I/II	NCT04821674
SARS-CoV-2	LNP-nCoVsaRNA (2.5, 5 or 10 $\mathrm{\mu }$g)	Imperial College London	I	ISRCTN17072692/2020-001209-22
SARS-CoV-2	MRT5500 (up to 13.5 $\mathrm{\mu }$g)	TranslateBio, Sanofi	I/II (abandoned)	NCT04798027
Zika virus	mRNA-1893 (30 or 100 $\mathrm{\mu }$g)	ModernaTX, Inc.	II	NCT04917861
Chikungunya virus	VAL-181388/mRNA-1388 (25, 50 or 100 $\mathrm{\mu }$g)	ModernaTX, Inc., DARPA	I	NCT03325075
H10N8 (Influenza)	VAL-506440/mRNA-1440 (25 or 100 $\mathrm{\mu }$g)	ModernaTX, Inc.	I	NCT03076385
H7N9 (Influenza)	VAL-339851/mRNA-1851 (10, 25 or 50 $\mathrm{\mu }$g)	ModernaTX, Inc.	I	NCT03345043
Rabies	CV7202 (2$\times$ 1 $\mathrm{\mu }$g)	CureVac AG	I	NCT03713086
Heart failure	AZD8601 (3 mg or 30 mg)	AstraZeneca	II	NCT03370887
Transthyretin-related (ATTR) familial amyloid polyneuropathy, cardiomyopathy, wild-type TTR cardiac amyloidosis	NTLA-2001 (0.1, 0.3, 0.7 or 1.0 mg/kg)	Intellia Therapeutics	I	NCT04601051
TTR-mediated amyloidosis, amyloidosis, hereditary, transthyretin-related	ALN-TTR02 (siRNA dose: 0.3 mg/kg, every 3 weeks for 18 mo.)	Alnylam Pharmaceuticals	FDA-approved (Onpattro/patisiran)	NCT01960348
Melanoma, colon, gastrointestinal, genitourinary or hepatocellular cancer	NCI-4650 (40, 130 or 390 $\mathrm{\mu }$g)	National Cancer Institute (NCI)	I/II	NCT03480152
Melanoma	FixVac (BNT111) (14.4, 50 or 100 $\mathrm{\mu }$g)	BioNTech SE	I	NCT02410733
Non-small-cell lung cancer (NSCLC)	mRNA-5671/V941 (dose unknown)	Merck Sharp & Dohme Corp.	I	NCT03948763
Triple-negative breast cancer (TNBC)	IVAC_W_bre1_ulD or IVAC_M_ulD (dose unknown)	BioNTech SE, Seventh Framework Program	I/II	NCT02316457
HPV-positive cancers (squamous cell carcinoma, head & neck neoplasm, cervical neoplasm, etc.)	HARE-40 (dose unknown)	University of Southampton, BioNTech SE	I/II	NCT03418480
Ovarian cancer	W_ova1 Vaccine (50 $\mathrm{\mu }$g, followed by 100 $\mathrm{\mu }$g total)	University Medical Center Groningen, BioNTech SE	I	NCT04163094
Solid tumors, cancer	MEDI1191 (dose unknown)	MedImmune LLC	I	NCT03946800

SARS-CoV-2 severe acute respiratory syndrome coronavirus-2, FDA United States Food and Drug Administration, EUA emergency use authorization, CMA conditional marketing authorization.